ConductScience.org, home

Trial · NCT02259114

Adverse events585

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersMK-8628 Continuous Dosing Regimen 80 mg/Day72019
otherAnaemiaBlood and lymphatic system disordersMK-8628 Continuous Dosing Regimen 100 mg/Day242
otherAnaemiaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 100 mg/Day3133
otherAnaemiaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 120 mg/Day131
otherAnaemiaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 160 mg/Day163
otherThrombocytopeniaBlood and lymphatic system disordersMK-8628 Continuous Dosing Regimen 80 mg/Day42010
otherThrombocytopeniaBlood and lymphatic system disordersMK-8628 Continuous Dosing Regimen 100 mg/Day040
otherThrombocytopeniaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 100 mg/Day0130
otherThrombocytopeniaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 120 mg/Day030
otherThrombocytopeniaBlood and lymphatic system disordersMK-8628 Days 1-7 Dosing Regimen 160 mg/Day060
otherFactor VII deficiencyCongenital, familial and genetic disordersMK-8628 Continuous Dosing Regimen 80 mg/Day4204
otherFactor VII deficiencyCongenital, familial and genetic disordersMK-8628 Continuous Dosing Regimen 100 mg/Day040
otherFactor VII deficiencyCongenital, familial and genetic disordersMK-8628 Days 1-7 Dosing Regimen 100 mg/Day0130
otherFactor VII deficiencyCongenital, familial and genetic disordersMK-8628 Days 1-7 Dosing Regimen 120 mg/Day030
otherFactor VII deficiencyCongenital, familial and genetic disordersMK-8628 Days 1-7 Dosing Regimen 160 mg/Day060
otherVision blurredEye disordersMK-8628 Continuous Dosing Regimen 80 mg/Day2205
otherVision blurredEye disordersMK-8628 Continuous Dosing Regimen 100 mg/Day040
otherVision blurredEye disordersMK-8628 Days 1-7 Dosing Regimen 100 mg/Day0130
otherVision blurredEye disordersMK-8628 Days 1-7 Dosing Regimen 120 mg/Day030
otherVision blurredEye disordersMK-8628 Days 1-7 Dosing Regimen 160 mg/Day060

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02259114/events